A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.
For adults with early-stage chronic kidney disease (CKD), a proprietary formula performed well in stratifying risk of progression to more severe kidney dysfunction and of increased healthcare needs.
Large international study confirms the importance of albuminuria in risk assessment. Investigators studied eGFR and albuminuria data from more than 27 million adults and their risk for 10 key adverse outcomes.
Findings from a meta-analysis are calling attention to the viability of classification and risk stratification using greater albuminuria and decreased eGFR.
Associations between modest reductions in kidney function and adverse outcomes in young adults: retrospective, population based cohort study bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.